Across TCGA pan-cancer cohorts, SLC35E2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC35E2B data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLC35E2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC35E2B expression acts as an unfavorable survival marker.

HNSC, SARC, and UCEC are the cancer types where SLC35E2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.098	0.710	<.001	12	view →
SARC	OS	Median	All	0.156	0.767	.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SLC35E2B tumor-vs-normal RNA expression · all SLC35E2B data types